Ipamorelin vs GHRP-6

In this post we’re comparing ipamorelin and GHRP-6, two popular growth hormone-releasing peptides (GHRPs). They have a lot in common but also some key differences. Both can be ordered from Loti Labs, a peptide and research company based in the USA.

What are GHRPs

They are made up of specific chains of amino acids so they’re often called synthetic peptides. Instead they activate different receptors either in the anterior pituitary gland or in the hypothalamus of the animal. Some formulations even allow for oral delivery making them versatile tools for researchers.

Ipamorelin and GHRP-6 Overview

Ipamorelin is a third generation peptide, after GHRP-6 which was the first one tested in animal studies. Ipamorelin targets GH release only, keeps other hormone levels steady.

What Are GHRPs (Repeated Section)

This triggers a chain reaction that results in more GH being pushed into the bloodstream.

Structural Differences Between GHRP-6 and Ipamorelin

Differences

Research on animal models show that each peptide activates ghrelin, sometimes called “the hunger hormone” and binds to its receptor.

This makes the response more targeted.

Ipamorelin does not touch cortisol and prolactin levels like GHRP-6. It breaks down slower than GHRP-6 giving it longer lasting effects.

GH Pulse Quality: Predictable vs. Potent

GH pulse characteristics differ meaningfully between the two compounds. Ipamorelin generates smaller, more physiological, and highly predictable GH pulses that closely mimic the body’s natural secretion pattern. Its longer half-life (~2 hours vs. GHRP-6’s ~20–30 minutes) sustains IGF-1 elevation for longer, making it preferable for anabolic signaling studies where consistency matters more than peak amplitude.

This effect is particularly relevant in hypogonadal models and aging populations where GH-axis activity declines.

Ipamorelin’s selective GH release without cortisol elevation makes it a cleaner compound for dermatology and aging research compared to non-selective GHRPs.

Disclaimer: Ipamorelin and GHRP-6 are research chemicals and not for human use.

Comparison: Ipamorelin vs.

Both Ipamorelin and GHRP-6 show similar results in animal studies but have different chemical structure. Key differences are in the table below.

GHRP-6 and Ipamorelin Comparison

GHRP-2: Another Growth Hormone Releasing Peptide

GHRP-2 is another member of the GHRP family and can also release GH strongly. Like GHRP-6 it binds to the ghrelin receptor to kick GH out of the pituitary gland.

Be careful though. GHRP-2 can also increase cortisol and prolactin and those increases can cause problems if you don’t monitor them. Monitor GH, cortisol and prolactin if you want to get the good stuff and avoid the bad stuff.

But the details of how GHRPs work on androgen receptors are still being explored. Also not all GHRPs bind to androgen receptors the same way.

Stacking GHRPs with Other Peptides

For example GHRP-6 with Ipamorelin can push GH levels higher than either one alone.

You want to raise GH levels noticeably without running into unwanted effects. Regular hormone monitoring and chats with qualified professionals is a must when testing peptide blends in a research setting.

Conclusion: Ipamorelin vs GHRP-6 Peptides

Your choice between GHRP-6 and Ipamorelin depends on your goal. Regardless of which one you choose Loti Labs guarantees top quality, lab grade, USA made peptides.

Where to Buy Research Peptides

You can get Ipamorelin and GHRP-6 now at Loti Labs. These research peptides are for studying and other body processes. Always choose USA made peptides for consistent results. Loti Labs tests GHRP-2, Ipamorelin and GHRP-6 with HPLC and mass spectrometry so you know they meet the highest standards. Ipamorelin comes in 2mg vials and GHRP-6 comes in 5mg, both as lyophilized powders. Buy your peptides now from Loti Labs!

References

Camanni, F., Ghigo, E., & Arvat, E. (1998). Growth Hormone-Releasing Peptides and Their Analogs. Frontiers in Neuroendocrinology, 19, 47-72. https://doi.org/10.1006/frne.1997.0158

Wu D, Chen C, Zhang J, Bowers CY, Clarke IJ. J Endocrinol. 1996;148(2):197–205. doi:10.1677/joe.0.1480197.

Rogério G. Gondo, Manuel H. Aguiar-Oliveira, César Y. Hayashida, Sergio P. A. Toledo, Neusa Abelin, Michael A. Levine, Cyril Y. Bowers, Anita H. O. Souza, Rossana M. C. Pereira, Norma L. Santos, Roberto Salvatori. J Clin Endocrinol Metab. 2001;86(7):3279–3283. https://doi.org/10.1210/jcem.86.7.7694.

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin: a selective GH secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552.

Johansen PB, Nowak J, Skjaerbaek C, et al. Growth Horm IGF Res. 1999;9(2):106–113. doi:10.1054/ghir.1999.9998.